Blog

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer
Conditions:   Breast Cancer;   Solid Tumor
Intervention:   Drug: OBT076, a CD205-directed antibody-drug conjugate
Sponsor:   Oxford BioTherapeutics Ltd
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 22, 2019 / by / in
ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
Conditions:   Pancreas Cancer;   Pancreas Cyst
Intervention:   Other: Lateral Flow Assay (LFA)
Sponsor:   Mayo Clinic
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 22, 2019 / by / in
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Condition:   Recurrent Glioblastoma
Intervention:   Drug: Regorafenib
Sponsor:   Case Comprehensive Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 22, 2019 / by / in
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
Condition:   Melanoma (Skin)
Interventions:   Drug: Aspirin 81 mg;   Drug: Aspirin 325mg
Sponsor:   University of Utah
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 21, 2019 / by / in
Exendin-9,39 and Satiety After Bariatric Surgery
Condition:   Obesity
Interventions:   Drug: Saline;   Drug: Exendin-9,39
Sponsors:   Mayo Clinic;   The Obesity Society
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 20, 2019 / by / in
Nobio Clinical Study
Conditions:   Dental Caries;   Denture, Partial, Removable
Interventions:   Device: Nobio composite;   Device: traditional composite
Sponsors:   University of California, San Francisco;   Nobio Ltd.
Enrolling by invitation

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 20, 2019 / by / in
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Conditions:   Pancreatic Adenocarcinoma;   Esophageal Adenocarcinoma;   Esophageal Squamous Cell Carcinoma;   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Triple Negative Breast Cancer;   Castration-resistant Prostate Cancer;   Microsatellite Stable Colorectal Cancer
Interventions:   Drug: GB1275;   Drug: nab-paclitaxel and gemcitabine;   Drug: pembrolizumab
Sponsor:   GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 20, 2019 / by / in
Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography
Condition:   Breast Cancer Screening
Intervention:   Diagnostic Test: QT Scanner
Sponsors:   QT Ultrasound LLC;   Analysis Group, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 20, 2019 / by / in
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Condition:   Sarcoma
Interventions:   Drug: TIL;   Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cyclophosphamide
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Iovance Biotherapeutics, Inc.;   The V Foundation for Cancer Research
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 20, 2019 / by / in
Nobio In Situ Clinical Study – Pilot Study
Conditions:   Dental Caries;   Denture, Partial, Removable
Interventions:   Device: Nobio composite;   Device: traditional composite
Sponsors:   University of California, San Francisco;   Nobio Ltd.
Enrolling by invitation

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 17, 2019 / by / in